Azithromycin ophthalmic solution, 1% + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blepharitis
Conditions
Blepharitis
Trial Timeline
May 1, 2009 → Dec 1, 2009
NCT ID
NCT00894530About Azithromycin ophthalmic solution, 1% + Placebo
Azithromycin ophthalmic solution, 1% + Placebo is a phase 2 stage product being developed by Merck for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00894530. Target conditions include Blepharitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01014078 | Approved | Completed |
| NCT00894530 | Phase 2 | Completed |
| NCT00892970 | Phase 2 | Completed |
Competing Products
15 competing products in Blepharitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lotilaner ophthalmic solution, 0.25% + Vehicle control | Tarsus Pharmaceuticals | Approved | 80 |
| TP-03 + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 3 | 72 |
| TP-03, 0.25% + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 2/3 | 60 |
| Lotilaner + Vehicle Control | LianBio | Phase 3 | 69 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone | Sun Pharmaceutical | Phase 3 | 77 |
| AzaSite® | Merck | Approved | 85 |
| AzaSite® | Merck | Approved | 85 |
| AzaSite® | Merck | Approved | 85 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 52 |
| AzaSite® | Merck | Approved | 85 |
| Azithromycin ophthalmic solution, 1% + Vehicle | Merck | Phase 2 | 52 |
| Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment | Viatris | Phase 3 | 74 |
| GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID | Glaukos | Phase 2 | 49 |
| KPI-121 + Vehicle | Kala Pharmaceuticals | Phase 2 | 44 |